$EW

Dahl Andrew M. sold $49K of EW

Dahl Andrew M. (SVP, Corporate Controller) sold 568 shares of Edwards Lifesciences Corp (EW) at $86.08 on 2026-05-29.

Original reporting
SEC EDGAR · Dahl Andrew M.
Published May 29, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 8:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

Provides a concrete insider trading datapoint (568 shares sold at $86.08; total ~$48.9K) without any accompanying corporate event.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a sustained repricing absent other catalysts.

03

What to watch

Insider sales can be scheduled around taxes/vesting, and the filing does not reveal intent, remaining compensation structure, or whether other insiders are buying/selling concurrently.

Relevance 6/10Novelty 6/10Timing: Filed 2026-05-29 (after market close) for an officer sale disclosed same day.

Background

The article is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences (EW).

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences disclosed an officer open-market sale of 568 shares at $86.08 on 2026-05-29 via SEC Form 4.

Expected impact

Low near-term impact; any reaction is likely noise unless followed by additional insider selling or material company news.

Evidence & confidence

The filing provides a specific transaction datapoint (size, price, date) but no new operational/financial catalyst; insider sales often have non-informational motives.

Market effects

Minor read-through only: single insider sale rarely resets sector expectations for medical devices.

None indicated; US-listed issuer-specific disclosure.

None indicated; no cross-border deal/regulatory event mentioned.

Counterpoint

Because the sale is small and not linked to a disclosed trading plan, it may reflect routine diversification or personal liquidity rather than bearish information.

Key entities

  • Edwards Lifesciences Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • Andrew M. Dahl

    SVP, Corporate Controller who sold 568 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMed

FDA Approves First Heart Valve to Keep Pace With Children's Growth

The FDA approved Edwards Lifesciences' Autus Size-Adjustable Valve, the first heart valve designed to expand with a child's growth, for pediatric patients with congenital pulmonary valve disease. The valve can be implanted at 13 mm and expanded to 22 mm, potentially reducing repeat open-heart surgeries. The approval was based on a pivotal trial with 62 patients, showing acceptable hemodynamic performance and no major complications at 6 months.

$EWHighAI 8/10

Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.